Investigators are developing models to predict the efficacy of DPP-4 inhibitors, GLP-1 RAs, SGLT-2 inhibitors, sulfonylureas, and thiazolidinediones to lower HbA1c levels using widely available clinical features (age, duration of diabetes, sex, baseline HbA1c, BMI, estimated glomerular filtration rate, HDL cholesterol, total cholesterol, and alanine aminotransferase) to facilitate therapy (14)
Minagawa A, Koga H, Saida T
For broader treatment placement in type 2 diabetes, see Injectable Type 2 Diabetes for context on when GLP-1 RAs complement other classes
Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials
When taken at therapeutic doses, approximately 90% of paracetamol is metabolised through conjugation pathways that produce harmless compounds excreted in urine
In response to this issue, numerous nanocarriers have been engineered for drug delivery to hypoxic tumors, encompassing hypoxia-responsive and pH-sensitive variants